Physician profile
Kathleen E Lukasik
NPI 1275684961
$1,799.51
in general payments reported to CMS, 2019-2025
23 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $622 · 2022: $619 · 2023: $176 · 2024: $205 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $557.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $379.15 | 2021-2025 | Rybelsus, Wegovy, Ozempic |
| Abbvie INC. | $317.77 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $230.60 | 2021-2022 | |
| Lilly USA, LLC | $155.72 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $121.23 | 2022-2025 | Airsupra, Farxiga |
| Eisai INC. | $79.66 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.78 | 2021-2022 | |
| Exact Sciences Corporation | $57.25 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $56.17 | 2021-2022 | |
| Pfizer INC. | $52.31 | 2023 | |
| Janssen Pharmaceuticals, INC | $35.51 | 2021 | |
| Idorsia Pharmaceuticals US INC | $28.51 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $26.79 | 2022-2023 | Verquvo, Belsomra |
| Abbott Laboratories | $25.96 | 2021 | |
| Astellas Pharma US INC | $23.00 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $22.04 | 2021 | |
| Bausch Health US, LLC | $22.03 | 2022 | |
| Jazz Pharmaceuticals INC. | $19.78 | 2021 | |
| Azurity Pharmaceuticals, INC. | $18.65 | 2025 | Alvesco |
| Biohaven Pharmaceuticals, INC. | $17.07 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.99 | 2021 | |
| Radius Health, INC. | $12.98 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Lukasik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.